Evaluation Of Efficacy, Safety And Tolerability Of NGM282 (Aldafermin) In A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study In Subjects With Compensated Cirrhosis Due To Nonalcoholic Steatohepatitis (ALPINE 4)
Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Inactive
The primary objective of this study is to evaluate the efficacy and safety of aldafermin compared to placebo.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.